LakeShore Biopharma Co., Ltd, a global biopharmaceutical company focused on vaccines and biologics for infectious diseases and cancer, has called an extraordinary general meeting of shareholders (EGM) to vote on a proposed merger that would take the company private. The EGM is scheduled for June 19, 2026, at 1:00 p.m. Beijing time at its Beijing headquarters, according to a press release issued today.
The meeting will consider and vote on the previously announced Agreement and Plan of Merger, dated November 4, 2025, as amended on April 29, 2026. Under the merger agreement, Oceanpine Merger Sub Inc., a wholly owned subsidiary of Oceanpine Skyline Inc., will merge with and into LakeShore Biopharma, with the company surviving as a wholly owned subsidiary of Oceanpine Skyline Inc. If approved, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will cease to be quoted on the OTC Pink tier of the OTC Markets and will be deregistered under the Securities Exchange Act of 1934.
The company's board of directors, acting on the unanimous recommendation of a special committee of independent directors, has authorized and approved the merger agreement and recommends that shareholders vote in favor. Shareholders of record as of 5:00 p.m. Cayman Islands time on May 27, 2026, are entitled to attend and vote at the EGM.
This development is significant for shareholders and the broader biopharmaceutical industry. For investors, the merger represents a potential exit from public trading, with shares no longer available on any public market. The move to go private could provide LakeShore Biopharma with greater flexibility to execute its long-term strategy without the quarterly pressures of public markets. The company, previously known as YS Biopharma, has developed a proprietary PIKA immunomodulating technology platform and targets vaccines for Rabies, Hepatitis B, Influenza, and other viruses, operating in China, Singapore, and the Philippines.
Additional details about the merger are available in the transaction statement on Schedule 13E-3 and the definitive proxy statement filed with the U.S. Securities and Exchange Commission (SEC). These documents, along with other relevant filings, can be accessed without charge on the SEC's website at http://www.sec.gov. Shareholders are urged to read these materials carefully as they contain important information about the proposed merger and related matters.
The company and certain directors and executive officers may be deemed participants in the solicitation of proxies. Information regarding such participants and their interests is set forth in the Schedule 13E-3 and proxy statement. The press release notes that forward-looking statements involve risks and uncertainties, including how shareholders will vote, the possibility of competing offers, and whether financing and closing conditions will be satisfied. The company undertakes no obligation to update these statements except as required by law.
For more information about LakeShore Biopharma, visit https://investors.lakeshorebio.com/. The outcome of the EGM will determine the future structure of the company and its presence in public markets.
